Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

By Catalona W.J.   Partin A.W.   Finlay J.A.   Chan D.W.   Rittenhouse H.G.   Wolfert R.L.   Woodrum D.L.  

Urology, Vol. 54, Iss. 2, 1999-08 ,pp. : 220-224

Elsevier

Access to resources Recommend Favorite

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

By Becker C.   Piironen T.   Pettersson K.   Hugosson J.   Lilja H.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 694-699

Elsevier

Access to resources Recommend Favorite

The funding for this work came in part from NIH Grant DK47656-05 and the Richard M. Lucas Foundation.Serum percent free prostate-specific antigen in metastatic prostate cancer - influence of total PSA, prostate volume, and age

By Lin D.W.   Noteboom J.L.   Blumenstein B.A.   Ellis W.J.   Lange P.H.   Vessella R.L.  

Urology, Vol. 52, Iss. 3, 1998-09 ,pp. : 366-371

Elsevier

Access to resources Recommend Favorite

Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL

By Okegawa T.   Noda H.   Nutahara K.   Higashihara E.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 700-704

Elsevier

Access to resources Recommend Favorite

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

By Krumholtz J.S.   Carvalhal G.F.   Ramos C.G.   Smith D.S.   Thorson P.   Yan Y.   Humphrey P.A.   Roehl K.A.   Catalona W.J.  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 469-473

Elsevier

Access to resources Recommend Favorite